


T2T Participant Newsletter



Season's Greetings

Thank you for taking part in the T2T Trial

A reminder of what the trial is about... Gout occurs due to high urate levels in the body which leads to urate crystals depositing in the joints. When shed from their deposits, the crystals cause painful gout flares. Medications such as allopurinol lower blood urate levels and dissolve urate crystal deposits. We are conducting a study to find out whether taking these medicines for several years prevents gout flares in people with gout.


2023 Annual Round-up



3412 patients
screened



671 patients
consented



404 patients
randomised

The trial began recruitment in November 2019. We have reached 404 out of 466 participants and hope to reach this target by early 2024. Even though recruitment was paused by COVID in March 2020, recruitment recommenced in March 2021 and patients were able to answer questionnaires online and by text message.

Just a reminder to:

- Take your study medications daily if in the treatment arm
- Report any gout flares to us
- Attend follow up appointments

We appreciate your continued support as the information we receive from both usual care and treat to target participants is vital to find out what is the best treatment to prevent gout flares.

If you need any new diaries, please let the team know and they will send these out to you

Contact the T2T Trial Manager: 01782 732950 or via email: sch-tr.t2tgout@nhs.net